← Trials/Trial dossier/NCT07282769

Not yet recruitingPhase 2

Semaglutide (Wegovy) Treatment for Trichotillomania

Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study

Asset

Semaglutide

GLP-1 agonist

Listed sites

0

Recruiting sites

Enrollment

10

estimated

Study population

Key I/E criterion

Primary endpoint

NIMH Trichotillomania Severity Scale

Identifiers

Registered as

NCT IDNCT07282769
Org study IDIRB25-1571

Timeline

Milestones

Study first posted2025-12-15actual
Last update posted2026-05-04actual
Study start2026-05estimated (month precision)
Primary completion2027-02estimated (month precision)
Study completion2027-02estimated (month precision)

Assets

Investigational agents

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Men and women age 18-75;

2. Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);

3. Hair pulling daily with urges to pull as the trigger in >50% of the episodes of pulling;

4. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;

5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence

Exclusion criteria

1. Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);

2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;

3. History of seizures;

4. Myocardial infarction within 6 months;

5. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;

6. A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator;

7. Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale);

8. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;

9. Current skin picking disorder;

10. Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;

11. Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed);

12. Previous treatment with semaglutide;

13. Use of any weight loss medications;

14. Body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23;

15. Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder;

16. Recent (30-day) use of illicit drugs except cannabis;

17. History of diabetes, and current medical or neurological illness precluding participation based on physician judgment;

18. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B;

19. History of pancreatitis.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
2
Other clinical outcomes
1

Patient-reported / QoL

2 endpoints
Secondary/protocol endpoint

Clinical Global Impression-Improvement and Severity Scales

Time frame:From screening to 1 week after last dose of study drug

PGI, change

change from baseline, improvement

Secondary/protocol endpoint

Massachusetts General Hospital Hair Pulling Scale

Time frame:From screening to 1 week after last dose of study drug

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

NIMH Trichotillomania Severity Scale

Time frame:From screening to 1 week after last dose of study drug

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.